Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)
European Journal of Cancer · 2026-05 · 238 · 116688
DOI: 10.1016/j.ejca.2026.116688 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2026-05. Verfasst von Yosuke Kito und 26 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan; Department of Medical Oncology, Ishikawa Prefectural Central Hospital…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Camptothecin, Antibodies, Monoclonal, Humanized, Colorectal Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Eli Lilly Japan KK, Taiho Pharmaceutical, Bristol-Myers Squibb.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan; Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan. Electronic address: kitoyo9100@gmail.com.
- Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan.
- Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan.
- Division of Gastroenterology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan.
- Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan.
- Department of Medical Oncology, Nagoya Medical Center, Aichi, Japan.
Förderung
- Eli Lilly Japan KK
- Taiho Pharmaceutical
- Bristol-Myers Squibb
Zitieren
APA
Kito, Y., Yamazaki, K., Shoji, H., Yamada, T., Tsushima, T., Mitani, S., Shiraishi, K., Yasui, H., Hara, H., Hirata, K., Esaki, T., Shinohara, Y., Tsuzuki, T., Kajiura, S., Masuishi, T., Izawa, N., Baba, E., Murata, K., Akazawa, N., …, & Muro, K. (2026). Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST). European Journal of Cancer, 238, 116688. https://doi.org/10.1016/j.ejca.2026.116688
Vancouver
Kito Y, Yamazaki K, Shoji H, Yamada T, Tsushima T, Mitani S, et al. Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST). European Journal of Cancer. 2026;238:116688. doi:10.1016/j.ejca.2026.116688
BibTeX
@article{Kito2026,
author = {Kito, Yosuke and Yamazaki, Kentaro and Shoji, Hirokazu and Yamada, Takeshi and Tsushima, Takahiro and Mitani, Seiichiro and Shiraishi, Kazuhiro and Yasui, Hisateru and Hara, Hiroki and Hirata, Kenro and Esaki, Taito and Shinohara, Yudai and Tsuzuki, Takao and Kajiura, Shinya and Masuishi, Toshiki and Izawa, Naoki and Baba, Eishi and Murata, Kohei and Akazawa, Naoya and Suzuki, Yozo and Satake, Hironaga and Boku, Narikazu and Hyodo, Ichinosuke and Yoshimura, Kenichi and Kawakami, Hisato and Hironaka, Shuichi and Muro, Kei},
title = {Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST)},
journal = {European Journal of Cancer},
year = {2026},
volume = {238},
pages = {116688},
doi = {10.1016/j.ejca.2026.116688}
}
EUVIMED